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Abstract 
Background: Scarce data exist on the efficacy and safety of the PEGylated-
interferon/ribavirin/boceprevir regimen in HIV/HCV-coinfected patients who failed to respond to 
PEGylated-interferon/ribavirin treatment.  
Objectives: To evaluate the efficacy and safety of this drug regimen .and the impact of the addition of 
boceprevir(BOC) on atazanavir(ATV) or raltegravir(RAL) pharmacokinetic parameters in a subgroup 
of patients. 
Methods: In this single-arm phase 2 trial, HIV-1/HCV-genotype-1-coinfected patients received 
PEGylated-interferonα2b(1.5μg/kg/week)+ribavirin(800-1400mg/day) alone until W4 and with 
BOC(800 mgTID) until W48. Based on virologic response at W8, the three drugs were stopped or 
PEGylated-interferon/ribavirin was continued alone until W72. The primary endpoint was SVR at 
W24 off-therapy (SVR24).  
Results: 64 patients were included. SVR24 was achieved in 53% of patients (CI90%: 43-63%) and in 
90% of previous relapsers. In univariate analysis, SVR24 was associated with response to previous 
HCV-treatment, HCV-1b subtype, HCV-RNA decline, ribavirin-Ctrough at W4, and HCV-RNA at W8 
but not to fibrosis score, IL28B genotype, or boceprevir-Ctrough at W8. In multivariate analysis, SVR24 
remained associated with response to previous HCV-treatment [non-responders versus null-
responders: OR= 5.0(1.3-20.0); relapsers versus null-responders: OR= 28.8(4.9-169.5)]. HCV 
treatment was discontinued for adverse events in 17% of patients. A 51% decrease in ATV/r-AUC0-8h 
(p < 0.01) and a 57% increase in RAL-AUC0-8h (p < 0.01) were observed, although atazanavir/r or 
raltegravir did not affect BOC-AUC0-8h significantly. The ATV mean Cthrough fell from 763.8 ng/mL 
(CI 95%: 230.3-1297.3) without BOC to 507.7 ng/mL (CI 95%: 164-851.4) with BOC.  
Conclusions: Boceprevir-based regimen demonstrated a high SVR24 rate in treatment-experienced 
HIV-HCV genotype 1 coinfected relapsers. 
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Introduction  
With the use of last generation direct active antiviral (DAA) drugs, the majority of HCV monoinfected 
and HIV/HCV coinfected patients will hopefully be cured 1, and in the majority of cases, with an 
interferon-free regimen. However, interactions between DAA and antiretroviral drugs remains an issue 
for HCV/HIV coinfected patients, and to date, access to interferon (IFN)-free regimens remains 
limited in many parts of the world. The objective of the ANRS HC27-BOCEPREVIH trial was to 
evaluate the efficacy and safety of the NS3 HCV protease inhibitor boceprevir (BOC) in combination 
with PEG-IFN/RBV in HIV/HCV-G1-coinfected patients who failed to respond to PEG-IFN/RBV. 
This trial included a pharmacokinetic sub-study evaluating the drug interaction between BOC and 
ritonavir-boosted atazanavir (ATV/r) or raltegravir (RAL) in order to further investigate previous 
observations in healthy volunteers regarding HIV protease inhibitors and to elucidate this issue with 
the integrase inhibitor RAL2.  
Methods 
Study design 
This single-arm, multicenter, open-label, phase 2 trial, enrolled HIV-1/HCV-G1 coinfected patients 
who had previously failed a treatment with PEG-IFN (α-2a or α-2b)/RBV (≥ 600 mg/day) during < 12 
weeks. Other inclusion criteria included stable (> 3 months) antiretroviral therapy with at least three 
drugs (among which abacavir, emtricitabine, lamivudine, tenofovir, ATV or ATV/r, and RAL), CD4 
cell count > 200 /mm3 and > 15%, and HIV-RNA < 50 copies/mL for at least 6 months. The primary 
exclusion criteria were HBV coinfection, Child-Pugh score B or C, and history of decompensated 
cirrhosis. Virological failure to previous therapy was classified as relapse, (i.e., undetectable HCV-
RNA at end of treatment and detectable HCV-RNA thereafter), breakthrough (i.e., undetectable HCV-
RNA at least once during treatment, becoming detectable thereafter under treatment), and non-
response including partial-response (i.e., > 2 log10 HCV-RNA decline at W12 and still detectable 
HCV-RNA at W24) and null-response (i.e., <2 log10 HCV-RNA decline at W12). The fibrosis score 
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was documented by a liver biopsy. Inclusion of non-cirrhotic null-responders was limited to 34% of 
patients. Cirrhotic patients with a previous null-response were excluded. The study protocol 
(EUDRACT number 2010-023450-36) was approved by Ethical Committee CPP-Sud-Méditerranée-1 
(Marseille, France) and the French Regulatory Authority ANSM (previously Afssaps, Paris, France). 
The protocol was registered in the ClinicalTrials.gov database under reference NCT01335529. It was 
conducted in compliance with the Declaration of Helsinki and ICH-GCP guidelines. All participants 
provided written informed consent. 
Procedures 
All patients received a lead-in phase with PEG-IFNα-2b/RBV during 4 weeks. BOC was added at the 
end of W4 (Figure 1). Total treatment duration was defined according to a patient’s status regarding 
rapid virological response (RVR) at the end of W8 (RVR8). A complete RVR8 was defined as HCV-
RNA < 15 IU/mL and a partial RVR8 as HCV-RNA between 15-1000 IU/mL. For patients with 
complete RVR8, total treatment duration was 48 weeks; SVR was evaluated at W72 (SVR24). For 
patients with partial RVR8, BOC was stopped at W48 but PEG-IFN/RBV was maintained for a total of 
72 weeks, and SVR24 was evaluated at W96. A dosage of 800mg BOC was prescribed (in 200 mg 
capsules) 3 times per day (7-9 hour interval between intakes) during meals. PEG-IFN (1.5 µg/kg) was 
administered subcutaneously once a week. Oral RBV was given at 800-1400 mg/day (weight-based) 
BID during meals. Erythropoietin (EPO), granulocyte-colony-stimulating factor (G-CSF) and 
thrombopoietin-receptor (TPO-R) agonists were allowed. Blood transfusions and RBV dose reduction 
were allowed only if EPO failed to maintain a hemoglobin concentration above 100 g/L. Futility rules 
for BOC were defined as an HCV-RNA > 1000 IU/mL at W8 or W12. For these patients, PEG-
IFN/RBV was maintained until W72, and SVR24 was evaluated at W96. BOC, PEG-IFN and RBV 
were interrupted if HCV-RNA was > 100 IU/mL at W16, if HCV-RNA was still detectable at W28 or 
at any time in the case of virological breakthrough.  
We defined virological breakthrough as confirmed HCV-RNA detection after prior undetectability. All 
non-responders (failure or breakthrough) received follow-up until W72 or W96 depending on the 
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HCV-RNA at W8. Virological relapse was defined as HCV-RNA undetectable at EOT, then 
detectable at the end of follow-up, without evidence of new HCV reinfection. 
Virological analysis 
HCV-RNA was quantified on site by real-time-PCR assays using RealTime-HCV (Abbott 
Diagnostics) or COBAS TaqMan-HCV (Roche Diagnostics) assays (lower limits of detection (LLD) 
of 12 and 15 IU/mL, respectively) and carried out by the same laboratory and assay throughout the 
study. For virological response assessment, detectable HCV-RNA was defined as HCV-RNA > 15 
IU/mL. Detectable HCV-RNA below LLD was considered positive with a value equal to LLD. 
Genotypic drug resistance testing was performed for all patients with virological failure, breakthrough, 
or relapse post-treatment. HCV-RNA was extracted from 200 μl serum with the EZ1-Virus Mini Kit 
v2.0 using the BioRobot EZ1 Workstation (Qiagen) following the manufacturer’s instructions. PCR 
amplification and direct population sequencing of the full-length HCV-NS3 protease gene were 
performed using in-house protocols as described previously 3. Amino-acid diversity was analyzed at 
sites associated with reduced susceptibility to BOC. HIV-RNA was measured with RealTime-HIV 
(Abbott Diagnostics) or COBAS TaqMan-HIV (Roche Diagnostics) assays. HIV viral load (VL) was 
considered detectable at > 50 copies/mL. A blip in HIV viral load was defined as a positive detectable 
HIV viral load lower than 1000 copies/mL becoming undetectable in a next measurement performed 
after a delay of 4 weeks.  
IL28B genotype (SNP rs12979860) was determined in all patients using peripheral blood mononuclear 
cell DNA by Sanger population sequencing 4, 5. 
Pharmacokinetic analysis 
Plasma RBV-Ctrough was determined at W4 using a high performance liquid chromatography-diode 
array detector (HPLC-DAD). A pharmacokinetic (PK) sub-study evaluating the drug interaction 
between BOC and ATV/r, or BOC and RAL was planned in a sub-group of 30 patients. Blood samples 
were collected at baseline for antiretroviral (ARV)and at W8 for both ARV and BOC. BOC-Ctrough was 
8 
 
8 
 
determined by a liquid-chromatography tandem-mass spectrometry method. PK parameters [Cmax, 
Ctrough and the area under the curve (AUCà-!h)] were determined at steady-state based on the PK profiles 
obtained with blood samples drawn at 0 (before ARV ± BOC intake), 1, 2, 3, 4, 6 and 8 h during an 8-
hour interval after intake of drugs with a standardized meal. PK analysis was performed by a non-
compartmental method (PK fit Software, Montpellier, France). The reported Cmax, Tmax and Ctrough are 
the values observed in individual PK profiles. Statistical analyses were performed by comparing mean 
PK parameters at baseline and W8 for ARV, and with historical data of BOC alone for BOC. Patients 
were classified according to RBV-Ctrough-W4 and BOC-Ctrough-W8 to evaluate the impact on SVR24. A 2 
µg/mL threshold was chosen for RBV according to the minimum recommended Ctrough reported under 
PEG-IFN/RBV 6. Because no efficacy threshold was established for BOC-Ctrough, the cut-off was set at 
the median value observed in our study (127 µg/L). 
Safety analysis 
Adverse events (AE) were graded by investigators according to the “ANRS-scale to grade the severity 
of adverse events in adults”. Non-life threatening AEs were managed by means of a dose reduction of 
PEG-IFN or RBV similarly to those previously described 7, 8. Monthly monitoring of HIV-VL during 
BOC exposure was initiated in March 2012 associated with ATV-Ctrough measurement at screening, at 
W48, or in case of HCV- or HIV-breakthrough, according to FDA and EMEA recommendations. An 
independent data and safety monitoring board regularly evaluated the safety and side-effects of study 
regimens. 
Statistical analysis 
The primary efficacy endpoint was SVR24 rate measured at W72 or W96 according to treatment 
duration. The analysis of the main endpoint was performed with a test comparing an observed to a 
theoretical proportion conducted in unilateral formulation with a type I error of 5%. The rate of SVR24 
below which the therapy would have no interest was fixed at 20% (null hypothesis). The rate of SVR24 
above which the therapy would bring a real benefit was fixed at 35% (alternative hypothesis). To 
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guarantee 90% power to detect such a 15% benefit and considering the statistical hypotheses, a 
minimum of 22 (out of 77) participants with a SVR24 were required to conclude that SVR rate is above 
20%. An intent-to-treat analysis was performed for all patients who initiated treatment. Cases of 
missing data for the primary endpoint were considered treatment failures. Secondary efficacy 
endpoints included RVR8 and SVR12. Safety endpoints included treatment-emergent AEs, laboratory 
abnormalities and deaths. Anemia and HCV- and HIV- breakthroughs were cautiously monitored. 
Data are presented as counts and percentages, or median and inter-quartile range (IQR), as 
appropriate. Association of baseline characteristics with SVR24 as well as pharmacological data (RBV-
Ctrough-W4, BOC-Ctrough-W8) were analyzed using Wilcoxon, Chi² or Fisher’s exact tests with a significant 
threshold of p < 0.05. Multivariate analysis was subsequently conducted using a logistic regression 
model. For this analysis, continuous variables were broken into two classes on the basis of their 
median values, except for pharmacological data, where the threshold was optimal (i.e., optimizing 
sensitivity and specificity). Statistical analyses were performed using SAS statistical software (version 
9.4;Cary, NC, USA). 
Results 
Sixty-nine patients were screened from May 2011 to April 2012, 64 patients were enrolled and started 
PEG-IFN/RBV, and 62 patients started BOC after the lead-in phase. The analysis was performed on 
these 64 patients (Fig. 1). The baseline characteristics of patients are presented in Table 1. Most were 
men (75%), with a median age of 49 years, most were infected with HCV-G1a (78%), and 39% had 
severe fibrosis or cirrhosis. The HCV viral load was more than 800,000 IU/mL in 77% of cases and 
IL28B CT/TT genotypes were detected in 64%. Thirty-three percent of patients were previous null-
responders, and 31% were relapsers. Half were treated with 2 NRTI+ATV/r, 42% with 2 NRTI+RAL 
and 8% with other authorized ART combinations. Among NRTIs, 92% were treated with tenofovir + 
emtricitabine. HIV-VL was detectable in 2 patients treated with an ATV/r-based regimen (60 and 176 
copies/mL, respectively) and in 1 patient treated with an RAL-based regimen (80 copies/mL). For 
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these 3 patients, HIV-VL was undetectable at screening and at W4, and remained undetectable 
throughout the follow up. 
 
Efficacy 
Sixty-two patients reached W4 (fig 1). At this time, one patient achieved undetectable HCV-RNA, 
while 28 patients (44%) had an HCV-RNA decrease ≥ 1 log10. Sixty-one patients reached W8, of 
whom 26 had a complete RVR8 and were assigned to continue PEG-IFN/RBV/BOC until W48. The 
rate of RVR8 was 27.3% among cirrhotic patients versus 24.5% among patients without cirrhosis. A 
partial RVR8 was observed in 21 patients and was re-evaluated at W12, and 14 participants had to stop 
BOC and continue PEG-IFN/RBV until W72. All of these 14 patients stopped the three drugs before 
W20 because of AE in one case, lack of efficacy in 7 and patient’s decision in 6. At W12, twenty 
patients with partial RVR8 had a partial response and were assigned to PEG-IFN/RBV/BOC until W48 
and then to PEG-IFN/RBV until W72. However, 14 patients stopped the treatment before W72 
because of AE in four cases, lack of efficacy in 2, breakthrough in 6 and patient’s decision in 2. One 
patient had to stop BOC and continue PEG-IFN/RBV until W72, but he decided to stop PEG-
IFN/RBV before W16. No patient died after the EOT.  
Overall, thirty-seven patients (58%) discontinued treatment either before (n = 3) or after (n = 34) W8, 
due to AEs in 11 patients (17%), virological breakthrough in 7 (11%), lack of efficacy in 9 (14%), 
patient’s decision in 9 (14%; 7 before W16), and investigator’s decision in 1. Thus, 27 patients (42%) 
terminated the study protocol.  
SVR24 was achieved in 34/64 patients (53%; 90% CI: 43%-63%; p = 0.002), including 7 patients who 
stopped HCV treatment prematurely following AEs (n = 5) or patient/investigator’s decision (n = 2), 
and was similar to SVR12. The SVR24 rate was 90% in relapsers and 79% in patients with HCV-G1b. 
Table 2 shows SVR24 according to baseline characteristics, virological response at W4 and at W8, 
RBV-Ctrough-W4 and BOC-Ctrough-W8. Among baseline characteristics, response to previous treatment, 
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RAL-based regimen, HCV-G1b, HCV-RNA < 6.4 log10 and HOMA > 2.5 were significantly 
associated with virological outcome. HCV-RNA decrease ≥ 1 log10 at W4, HCV-RNA < 15 IU/mL at 
W8 and RBV-Ctrough ≥ 2 µg/mL at W4 were also significantly associated with virological outcome. In 
multivariate analysis, response to previous treatment was the only significant variable associated with 
SVR24 for previous non responders versus null-responders (OR 5.0; CI: 1.3; 20.0) and for relapsers 
versus null-responders (OR 28.8; CI: 4.9; 169.5). 
 
Resistance 
The full-length HCV-NS3 protease gene was sequenced for 13 patients out of 23 who stopped 
treatment after HCV breakthrough, partial response, or patient’s/investigator’s decision. Eleven were 
infected with HCV-G1a. Clinically relevant amino-acid substitutions, absent at baseline, were detected 
in 7 patients (Table 3). They included mostly R155K and V36M/A, and substitutions T54A and T54S 
were observed in 1 case each. V36A, T54A and R155K were concurrently detected in HCV-G1a from 
1 patient.  
Pharmacokinetics 
The median RBV-Ctrough was 1.70 g/mL (IQR: 1.39; 2.13) and was not significantly different (p = 
0.36) between patients who achieved SVR24 and those who did not: 1.75 g/mL (IQR: 1.39; 2.66) 
versus 1.70 g/mL (IQR: 1.45; 1.91), respectively. However, 72.2% of patients who achieved SVR24 
had a, RBV-Ctrough up to 2 g/mL versus 27.8% of patients who did not (p = 0.03). The median BOC-
Ctrough was 127 g/L (IQR: 104; 308) and was not significantly different (p = 0.40) between patients 
who achieved SVR24 or not: 163 g/L (IQR: 100; 458) versus 125 g/L (IQR: 104; 255), respectively. 
Moreover, 52.4% of patients who achieved SVR24 had a BOC-Ctrough up to 127 µg/L versus 47.6% of 
patients who did not achieve SVR24 (p = 0.63). 
Twelve patients (10 males) fully completed the PK study, 7 on ATV/r and 5 on RAL, associated with 
12 
 
12 
 
tenofovir + emtricitabine (Table 4). A decrease in ATV/r-AUC0-8h of 51% (p < 0.01) and an increase in 
RAL-AUC0-8h of 57% (p < 0.01) were observed at W8. ATV and RAL-Ctrough were, respectively, 34% 
and 54% lower after initiation of BOC, but these variations did not reach statistical significance and 
the values remained above target concentrations for both drugs. ATV/r or RAL did not significantly 
affect BOC-AUC0-8h, compared with historical controls 9. Variations in BOC-Ctrough and Cmax were 
observed when associated with ATV/r or RAL, but they did not reach statistical significance. 
Safety 
AEs, dose modifications, and study drug discontinuation are summarized in Supplementary Tables 1 
and 2. The AEs most commonly observed were asthenia and flu-like symptoms. Grade 4 AEs occurred 
in 20 patients and included leukoneutropenia (6%), infections (6%), anemia (3%) and general 
disorders (3%). Although they were more frequent in patients with a severe fibrosis score, such events 
were observed in 23.8% and 22.2% of patients with F0/F1 and F2 fibrosis score, respectively.”Eleven 
(17%) patients discontinued treatment due to an AE. Four suspected unexpected serious adverse 
reactions (SUSAR) were reported. Two participants experienced sepsis, one had a generalized rash, 
and the other experienced acute pyelonephritis. All resolved. The two cases of sepsis were considered 
as strongly related to PEG-IFN even when they were observed under the combination of PEG-
IFN/RBV and BOC. The investigator and sponsor considered those events as possibly related to study 
medication. No death occurred. Three patients reported anemia as a serious AE (SAE) but did not 
discontinue the study. Most patients with anemia received EPO (38 patients) or had a PEG-IFN or 
RBV dose reduction (in 2 and 13 patients, respectively), and 8 received a transfusion. G-CSF was 
administered to 7 patients for neutropenia. Two patients discontinued the study drug because of 
neutropenia (neither was infection-related) or thrombocytopenia.  
During BOC exposure, 6 patients (ATV/r- and RAL-based regimen, n = 3 each) presented with one 
blip of HIV-VL, but no HIV breakthrough was observed. The median CD4 cell count decreased in 
absolute value from 728/mm3 [527-923] to 452/mm3 [301-639] at W48, but this value increased in 
percentage from 36% (IQR: 30-42) to 41% (IQR: 35-45). At W96, the percentage of CD4 cells 
13 
 
13 
 
returned to baseline (35%; IQR: 31-40) but remained lower in absolute value (641/mm3 (483-895). 
Discussion 
In this trial, the addition of BOC to PEG-IFN/RBV in HIV/HCV-coinfected patients who previously 
failed PEG-IFN/RBV led to an SVR24 rate of 53%, quite similar to that observed in both naive HCV-
monoinfected (59 to 66%) and HIV/HCV-coinfected (63%) patients 10, 11. More interestingly, the 
SVR24 rate reached 90% in patients who had previously relapsed after PEG-IFN/RBV therapy and 
61% in patients with previous partial response. These rates are higher than those observed in 
previously treated HCV-monoinfected patients (up to 75% and 52%, respectively) 10.  
Interestingly, among 28 patients with a decrease in HCV-RNA < 1 log10 at W4, addition of BOC 
allowed for the achievement of SVR24 in 21 (75%) cases. Moreover, patients with undetectable HCV-
RNA at W8 were shown to have an SVR24 rate of 88.5%, including 2 patients who stopped treatment 
prematurely (at W26 and W29) following AEs. Thus, patients who had an early response could benefit 
from shorter treatment. This hypothesis is consistent with recent reports of a response-guided 
shortening of BOC-based tri-therapy in HIV/HCV-coinfected patients 12. However, the design of this 
study did not allow us to assess this hypothesis. 
The limited impact of IL28B polymorphism was already described in naive coinfected patients treated 
with BOC10. As already reported, patients with HCV-G1 subtype 1b tended to achieve slightly higher 
SVR rates, as well as relapsers and previous partial-responders compared to other patients 13. The fact 
that the SVR24 was significantly higher among patients with insulin resistance confirms that the 
negative predictive factors previously determined for PEG-IFN/RBV therapy are no longer relevant 
with DAA. In contrast, some differences in SVR rates were observed among ART regimens (higher in 
patients treated with an RAL-based regimen = 70%), but patients were not randomized according to 
their cART regimen. Moreover, this result could be explained by a higher proportion of null-
responders among patients treated with ATV/r-based regimen (41% versus 22%). 
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We report a significant impact of RBV-Ctrough-W4 on SVR24, confirming that a threshold of ≥2 µg/mL 
remains crucial for optimizing the virological response to an RBV-based therapy. In contrast, BOC-
Ctrough-W8 did not appear significantly to affect the rate of SVR24. This could be explained by the large 
pharmacokinetic variability of BOC observed among our patients. 
Twenty patients (33%) reported at least one SAE, and 17% discontinued treatment following an AE. 
Furthermore, no drug interactions occurred and the observed safety was consistent with previous 
reports 10, 11. Similar to the CUPIC study 14, the rate of SAE was higher in patients with severe fibrosis. 
Significant hematological toxicity resulting in treatment withdrawal was observed in only 2 patients 
(3%), as a result of a proactive management of anemia (59% of patients). The prevalence and 
distribution of amino-acid substitution detected in 7 patients were similar to those previously reported 
3. 
A few sets of ART regimens were allowed in this trial because data on BOC-ART interactions were 
not available at the beginning of the study. Nevertheless, no HIV breakthrough was observed. The 
results of our PK sub-study are consistent with observations made in healthy volunteers. A trend 
towards lower ATV exposure when combined with BOC, with a significant AUC reduction, was 
observed. This was neither significant nor clinically relevant, as ATV-Ctrough still remained largely 
above the 200 ng/ml recommended threshold. However, even though ATV-Ctrough remained largely 
above the 200 ng/ml recommended threshold and we did not observe any HIV virological failure, our 
data suggest careful HIV RNA monitoring in patients receiving combinations of BOC with ATV/r. 
The substantial variability in RAL-PK parameters also suggest the need for careful monitoring of 
tolerance, even if we did not observed related adverse events in our trial. There was also a substantial 
variability in RAL-PK parameters without any clinical significance. Pending more data, we suggest 
careful HIV-RNA monitoring in patients receiving combinations of BOC with ATV/r and, to a lesser 
extent, RAL. 
There are several limitations to this trial. First, it is a non-randomized trial with a small sample size. 
Concerning the PK study, we could not include the number of planned patients. Finally, only 27 
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patients (42%) completed the study according to the protocol, with a high number of discontinuations 
due to patient’s decision. 
 
In conclusion, addition of BOC to PEG-IFN/RBV for HIV/HCV-coinfected patients who previously 
failed PEG-IFN/RBV led to an SVR24 rate of 53%, but this group included up to 90% in patients who 
previously relapsed after PEG-IFN/RBV therapy. Severe adverse events were reported in 20 patients 
and were more frequent in patients with severe fibrosis, and proactive management of anemia should 
be performed for patients administered this therapeutic combination. The pharmacological data justify 
maintaining a close monitoring of HIV-VL for patients treated with an ATV/r-based regimen, and a 
shorter regimen might be considered for patients with RVR8. Such a therapeutic option might be 
considered in countries where treatment of hepatitis C infection with the newer direct-acting antiviral 
drugs remains difficult because of the lack of availability, as recently emphasized 15. 
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Table 1: Baseline demographics and clinical characteristics 
  N (%), n=64 
Age, year, median [IQR] 49 [46-52] 
Gender, Male 48 (75%) 
Ethnicity, Non-Black 61 (95%) 
IVDU 47 (73%) 
BMI ≥25 Kg/m2 18 (28%) 
Response to previous HCV-treatment  
 Relapse 20 (31%) 
 Breakthrough 5 (8%) 
 Partial response 18 (28%) 
 Null-response 21 (33%) 
CDC stage C 14 (22%) 
CD4, cells/mm3, median [IQR] 
Nadir <200/mm3 
728 [527-923] 
35 (55%) 
HIV-RNA <50 copies/mL 61 (95%) 
Antiretroviral treatment  
 2 NRTIs*+ATV/r 32 (50%) 
 2 NRTIs+RAL 27 (42%) 
 Other ** 5 (8%) 
HCV-genotype  
 1a 50 (78%) 
 1b 14 (22%) 
19 
 
19 
 
  N (%), n=64 
HCV-RNA, log IU/mL, median [IQR] 
HCV-RNA >800 000 IU/mL 
6.4 [5.9-6.7] 
49 (77%) 
 
HOMA (n=54), median [IQR] 
> 2.5 
3.2 [1.9-6.2] 
36 (67%) 
IL28B-genotype (n=63)  
 CC 22 (35%) 
 CT 31 (49%) 
 TT 10 (16%) 
Fibrosis score   
 F0/F1 21 (33%) 
 F2 18 (28%) 
 F3 14 (22%) 
 F4 11 (17%) 
* NRTIs: TDF+FTC=57; ABC+3TC=2; 
** Other ART regimens: TDF+ATV/r+RAL=2; FTC+ATV/r+RAL=1; 
TDF+FTC+ATV/r+RAL=1; TDF+FTC+ATV+RAL=1 
Data are n (%) unless otherwise specified.. IQR = Inter Quartile Range. IVDU = Intra-
Venous-Drug-Use. BMI = Body-Mass Index. HCV = Hepatitis C Virus. CDC = Center for 
Diseases Control. NRTI = Nucleoside Reverse Transcriptase Inhibitor. ABC = abacavir. ATV 
= atazanavir. ATV/r = ritonavir- boosted atazanavir. FTC = emtricitabin. 3TC = lamivudin. 
RAL = raltegravir. TDF = tenofovir. HOMA = Homeostasis Model Assessment. IL28B = 
Interleukin-28B. 
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Table 2: SVR24 rate according to baseline characteristics, week 4 and week 8 virological 
responses, ribavirin Ctrough at week4 and BOC Ctrough at week8 
  SVR24 
n=34 
No SVR24 
n=30 
p-value* 
Age < 50 years 19 (52.8%) 17 (47.2%) 0.9497 (a) 
≥ 50 years 15 (53.6%) 13 (46.4%) 
Gender Male 24 (50.0%) 24 (50.0%) 0.3855 (a) 
Female 10 (62.5%) 6 (37.5%) 
Ethnicity Black 2 (66.7%) 1 (33.3%) 1.0000 (b) 
Non-black 32 (52.5%) 29 (47.5%) 
IVDU Yes 23 (48.9%) 24 (51.1%) 0.2642 (a) 
No 11 (64.7%) 6 (35.3%) 
BMI < 25 Kg/m2 
≥ 25 Kg/m2 
23 (50.0%) 
11 (61.1%) 
23 (50.0%) 
7 (38.9%) 
0.4232 (a) 
Response to previous 
HCV-treatment 
Relapse 18 (90.0%) 2 (10.0%) <0.0001 (b) 
Breakthrough 0 (0.0%) 5 (100.0%)  
Partial response 11 (61.1%) 7 (38.9%)  
Null-response 5 (23.8%) 16 (76.2%)  
CDC stage A/B 26 (52.0%) 24 (48.0%) 0.7332 (a) 
C 8 (57.1%) 6 (42.9%) 
CD4, cells/mm3 < 350 3 (60.0%) 2 (40.0%) 1.0000 (b) 
≥ 350 31 (52.5%) 28 (47.5%) 
Antiretroviral treatment 
(n=59) 
2 NRTIs + ATV/r 13 (40.6%) 19 (59.4%) 0.0223 (a) 
2 NRTIs + RAL 19 (70.4%) 8 (29.6%) 
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  SVR24 
n=34 
No SVR24 
n=30 
p-value* 
HCV-genotype 1a 23 (46.0%) 27 (54.0%) 0.0309 (a) 
1b 11 (78.6%) 3 (21.4%) 
HCV-RNA, log IU/mL < 6.4 21 (65.6%) 11 (34.4%) 0.0451 (a) 
≥ 6.4 13 (40.6%) 19 (59.4%) 
HOMA (n=54) ≤2.5 
>2.5 
5 (27.8%) 
22 (61.1%) 
13 (72.2%) 
14 (38.9%) 
0.0209 (a) 
IL28B-genotype (n=63) CC 12 (54.5%) 10 (45.5%) 0.7897 (a) 
CT 15 (48.4%) 16 (51.6%) 
TT 6 (60.0%) 4 (40.0%) 
Fibrosis score  F0-F2 22 (56.4%) 17 (43.6%) 0.5107 (a) 
F3-F4 12 (48.0%) 13 (52.0%) 
HCV-RNA decrease at 
W4 (n=62) 
< 1 log 13 (38.2%) 21 (61.8%) 0.0038 (a) 
≥ 1 log 21 (75.0%) 7 (25.1%) 
HCV-RNA-W8 Undetectable 
Detectable 
15 (93.8%) 
19 (39.6%) 
1 (6.3%) 
29 (60.4%) 
0.0002 (a) 
RBV-Ctrough-W4 (g/mL) 
(n=59) 
< 2 
≥ 2 
17 (41.5%) 
13 (72.2%) 
24 (58.5%) 
5 (27.8%) 
0.0296 (a) 
BOC-Ctrough-W8 (g/L) 
(n=41) 
< 127 
≥ 127 
9 (45.0%) 
11 (52.4%) 
11 (55.0%) 
10 (47.6%) 
0.6365 (a) 
Chi-square test (a) or Fisher exact test (b) Data are n (%) unless otherwise specified; IVDU = Intra-
Venous-Drug-Use. CDC = Center for Diseases Control. NRTI = Nucleoside Reverse Transcriptase 
Inhibitor. ATV/r = ritonavir-boosted atazanavir. RAL = raltegravir. HCV = Hepatitis C Virus. HOMA 
= Homeostasis Model Assessment. RBV = ribavirin. BOC = Boceprevir 
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Table 3: Resistance profile in patients with virological failure 
Patient Response to 
previous 
treatment 
HCV 
Genotype 
Baseline 
Mutations 
Time of 
failure 
log HCV 
RNA 
(IU/mL) 
Emerging 
Mutations 
Reason for 
therapy 
discontinuation  
1 Null 
responder 
1a WT W12 7,41 V36M, 
R155K 
Patient's 
decision 
2 Null 
responder 
1a WT W16 7,12 V36M, 
R155K 
Virologic 
failure 
3 Null 
responder 
1a WT W8 6,39 V36V/M, 
R155R/T/K 
Virologic 
failure 
4 Breakthrough 1a WT W8 5,57 V36V/A, 
T54T/A, 
R155R/K, 
I170I/V 
Virologic 
failure 
5 Null 
responder 
1a WT W8 5,88 R155K Patient's 
decision 
6 Null 
responder 
1a WT W8 6,36 V36V/M Virologic 
failure 
7 Null 
responder 
1b WT W28 6,7 T54S, 
A56S, 
I170V 
Virologic 
failure 
All patients had wild type at baseline. 
WT = wild type. 
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Table 4 : Pharmacokinetic parameters of ritonavir-boosted atazanavir, raltegravir and 
boceprevevir 
 AUC0-8h 
(μg/L.h) 
p-
value 
Ctrough 
(μg/L) 
p-
value 
Cmax 
(μg/L) 
p-
value 
ATV/r -BL 13212 ± 6620 <0.01 764 ± 754 NS(2) 2413 ± 1514 NS(2) 
ATV/r -W8 
with BOC(1) 
6533 ± 3178  508 ± 486  1418 ± 793  
RAL –BL  5901 ±6167 <0.01 338 ± 348 NS(2) 1387 ± 1478 NS(2) 
RAL-W8 
with BOC(1) 
9249 ±3032  154 ± 115  3556 ± 1408 - 
BOC-W8 
with ATV/r(3) 
4170 ± 1048 NS(2) 154 ± 89.2 NS(2) 1315 ± 458 NS(2) 
BOC-W8 
with RAL(3) 
5310 ± 2643 NS(2) 118 ± 79.5 NS(2) 1040 ± 574 NS(2) 
(1) ATV/r and RAL mean PK parameters were compared between baseline and W8 
(2) NS: not statistically significant; BL: Baseline 
(3) BOC mean PK parameters were compared with published data [29]. 
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